Resistell proposes a faster alternative to current Antimicrobial Susceptibility Testing (AST) diagnostic in SEPSIS patients. Resistell AST (RAPID-SEP-AST) is based on proprietary nanomotion detection technology that measures nanoscale motion (vibration) caused by living bacteria. In the presence of an effective antibiotic, bacteria die and motion ceases, indicating that the bacterial infection can be treated with that specific antibiotic. RAPID-SEP-AST takes 2-4h to provide diagnostic results, a contrast with the average of 24h that other current market leading AST diagnostics take. This allows RAPID-SEP-AST to guide the treatment of patients with time-sensitive clinical process, such as SEPSIS, which requires the start of antibiotic therapy within three hours of infection. Currently, SEPSIS patients are treated with empirical broad-spectrum therapies that target multiple bacteria due to the lack of rapid AST diagnostics to guide specific treatments. Although lifesaving, this approach causes inadequate treatment in 40% of patients and leads to the development of antimicrobial resistance (AMR), a current global threat.